A MUST-SEE Webinar!

Tuesday Dec 15th 2015 at 2pm EST
How: Pre-register at: webinar.camginc.com
Cost: FREE

Onglyza & Kombiglyze Heart Failure Webinar
AstraZeneca’s Clinical Trial Finds
Drugs Cause Heart Failure!

Onglyza Kombiglyze Heart Failure

Guest Speakers:

Timothy Clark and Robert Mosier from Sanders Phillips Grossman

Timothy Clark & Robert Mosier Headshots


What you can look forward to learning:

  • Who are the defendants and potential Plaintiffs?
  • What are the drugs and what supports causation?
  • Where is the battlefield?
  • How will we win?

Some information about Timothy Clark and Robert Mosier, your speakers and expert in this area of practice:

  • 3 years prosecuting Incretin Mimetic cases, including Byetta Pancreatitis settlement
  • Lead discovery general causation and liability, including expert development and depositions
  • Risperdal Lead Counsel

When: Tuesday Dec 15th 2015 at 2pm EST
How: Pre-register at: webinar.camginc.com
Cost: FREE


Pre-registration is required. Please register now by going to the following link:

http://webinar.camginc.com

Log in approximately 5 minutes before the webinar is supposed to begin, and you will automatically join the call.


Onglyza/Kombiglyze XR and Heart Failure

The Saxagliptin drugs, Onglyza (Approved 2009) and Kombiglyze XR (Approved 2010), treat Type II Diabetes. The drugs are used by hundreds of thousands of patients in the US. 2014 US sales accounted for nearly half a billion in revenue to AstraZeneca. Year over year growth predicts annual sales revenue to top one billion by 2018. However, Onglyza and Kombiglyze XR have a BIG problem…according to AstraZeneca’s own clinical trial, and one of the largest Randomized Controlled Clinical Trials in FDA history (a trial known as SAVOR), Saxagliptin drugs cause Heart Failure and AstraZeneca has NEVER warned of the risk!

On April 14, 2015, following an extensive review of the SAVOR trial data by FDA, an FDA Advisory Committee Meeting re Saxagliptin and cardiovascular safety convened to assess the statistically significant findings of Heart Failure. The Committee voted 14 vs. 1, recommending to FDA that Heart Failure risks should be added to the Onglyza and Kombiglyze XR labels. The single vote against the label change thought adding Heart Failure to the labels was insufficient given the risk and the drugs should be pulled from the market. AstraZeneca has known of the Heart Failure risk since at least 2013, but the drugs still do NOT warn of the injury.

Please join us for the most current info on Onglyza & Kombiglyze litigation updates, and the criteria to identify clients that have suffered from serious injuries as a result.